Aerovate Therapeutics Statistics Share Statistics Aerovate Therapeutics has 28.98M
shares outstanding. The number of shares has increased by 0.41%
in one year.
Shares Outstanding 28.98M Shares Change (YoY) 0.41% Shares Change (QoQ) 0% Owned by Institutions (%) 3.12% Shares Floating 341.84K Failed to Deliver (FTD) Shares 43,862 FTD / Avg. Volume 548.76%
Short Selling Information The latest short interest is 4.59M, so 15.85% of the outstanding
shares have been sold short.
Short Interest 4.59M Short % of Shares Out 15.85% Short % of Float 40.12% Short Ratio (days to cover) 16.61
Valuation Ratios The PE ratio is -38.07 and the forward
PE ratio is -3.39.
Aerovate Therapeutics's PEG ratio is
2.54.
PE Ratio -38.07 Forward PE -3.39 PS Ratio 0 Forward PS 3.8 PB Ratio 34.68 P/FCF Ratio -37.23 PEG Ratio 2.54
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Aerovate Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 20.93,
with a Debt / Equity ratio of 0.01.
Current Ratio 20.93 Quick Ratio 20.93 Debt / Equity 0.01 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-17.41M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 55K Effective Tax Rate -0.08%
Stock Price Statistics The stock price has increased by -95.55% in the
last 52 weeks. The beta is 0.95, so Aerovate Therapeutics's
price volatility has been higher than the market average.
Beta 0.95 52-Week Price Change -95.55% 50-Day Moving Average 88.53 200-Day Moving Average 81.25 Relative Strength Index (RSI) 58.33 Average Volume (20 Days) 7,993
Income Statement
Revenue n/a Gross Profit n/a Operating Income -74.6M Net Income -69.63M EBITDA -74.31M EBIT -74.6M Earnings Per Share (EPS) -2.44
Full Income Statement Balance Sheet The company has 33.75M in cash and 417K in
debt, giving a net cash position of 33.33M.
Cash & Cash Equivalents 33.75M Total Debt 417K Net Cash 33.33M Retained Earnings -233.05M Total Assets 77.53M Working Capital 74.96M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -71.2M
and capital expenditures 0, giving a free cash flow of -71.2M.
Operating Cash Flow -71.2M Capital Expenditures n/a Free Cash Flow -71.2M FCF Per Share -2.49
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields AVTE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for AVTE is $70,
which is 2511.9% higher than the current price. The consensus rating is "Hold".
Price Target $70 Price Target Difference 2511.9% Analyst Consensus Hold Analyst Count 7
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 29, 2025. It was a
backward
split with a ratio of 1:35.
Last Split Date Apr 29, 2025 Split Type backward Split Ratio 1:35
Scores Altman Z-Score 13.38 Piotroski F-Score 1
